All In Biotech

Drug Trial Radar · NCT04776746

Open-Label Extension Study of Trofinetide for Rett Syndrome

An Open-Label Extension Study of Continuing Treatment With Trofinetide for Rett Syndrome

Last checked: Nov 19, 2026Latest source record: Sep 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

77

Actual

Start

Nov 8, 2020

Primary completion

Jun 30, 2023

Study completion Jun 30, 2023

Sponsor

Lead sponsor
ACADIA Pharmaceuticals Inc.Industry
Sponsor type
Industry
First posted
Mar 2, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 5 years, up to 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To investigate the safety and tolerability of continued long-term treatment with oral trofinetide in girls and women with Rett syndrome

Conditions

  • Rett Syndrome

Interventions

  • trofinetideDrug

    Study drug is administered twice a day for up to approximately 32 months. Doses may be taken orally or administered by gastrostomy (G) tube. The subject's assigned dose for this study will be the final dose from the antecedent study (ACP-2566-004).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Patients With Treatment-emergent Adverse Events (TEAEs), With Serious Adverse Events (SAEs), and With Withdrawals Due to AEsTime frame: Mean study drug exposure was 426 days, corresponding to 1.2 years
  2. Number (%) of Patients With Potentially Clinically Important Changes in ECG Post-baselineTime frame: Mean study drug exposure was 426 days, corresponding to 1.2 years
  3. Number (%) of Patients With Potentially Clinically Important Changes in Vital Signs Post-baselineTime frame: Mean study drug exposure was 426 days, corresponding to 1.2 years
  4. Number (%) of Patients With Potentially Clinically Important Changes in Body Weight Post-baselineTime frame: Mean study drug exposure was 426 days, corresponding to 1.2 years
  5. Number (%) of Patients With Potentially Clinically Important Changes in Laboratory Parameters Post-baselineTime frame: Mean study drug exposure was 426 days, corresponding to 1.2 years

Locations

21 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Translational Genomics Research Institute (TGen)

    Phoenix, Arizona

  • University of California, San Diego

    La Jolla, California

  • UC Davis MIND Institute

    Sacramento, California

  • Children's Hospital Colorado Aurora

    Aurora, Colorado

  • University of South Florida

    Tampa, Florida

  • Emory Genetics Clinical Trial Center

    Atlanta, Georgia

  • Rush University Medical Center

    Chicago, Illinois

  • Kennedy Krieger Institute, John Hopkins School of Medicine

    Baltimore, Maryland

  • Boston Children's Hospital Harvard Medical School

    Boston, Massachusetts

  • Gillette Children's Specialty Healthcare

    Saint Paul, Minnesota

  • Washington University School of Medicine

    St Louis, Missouri

  • Montefiore Medical Center

    The Bronx, New York

  • The University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio

  • Cleveland Clinic

    Cleveland, Ohio

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • Greenwood Genetic Center

    Greenwood, South Carolina

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • Texas Children's Hospital

    Houston, Texas

  • Seattle Children's Hospital

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.